<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05620784</url>
  </required_header>
  <id_info>
    <org_study_id>STU00217795</org_study_id>
    <nct_id>NCT05620784</nct_id>
  </id_info>
  <brief_title>Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP</brief_title>
  <official_title>Loop Diuretics During Morcellation to Improve Same-day Discharge Rates After Holmium Laser Enucleation of the Prostate (HoLEP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Holmium Laser Enucleation of the Prostate (HoLEP) is a size-independent treatment option for&#xD;
      benign prostatic hypertrophy (BPH) as recommended by the American Urological Association&#xD;
      (AUA) Guidelines. Loop diuretics (furosemide) have been given historically during the&#xD;
      morcellation portion of HoLEP to promote urine production in the post-operative setting and&#xD;
      to minimize the impact of fluid absorption during long periods of morcellation. The&#xD;
      intra-operative use of 20mg IV furosemide in perioperative HoLEP pathways has been propagated&#xD;
      with the dissemination of HoLEP across North America without evidence to support its routine&#xD;
      administration. With increasing surgical efficiency from improvements in laser and&#xD;
      morcellator technology, the role of intra-operative furosemide is unknown. This study is&#xD;
      designed to assess if there is a significant difference in same day discharge rates after&#xD;
      Holmium Laser Enucleation of the Prostate (HoLEP) with and without IV furosemide. .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Holmium Laser Enucleation of the Prostate (HoLEP) is a size-independent treatment option for&#xD;
      benign prostatic hypertrophy (BPH) as recommended by the American Urological Association&#xD;
      (AUA) Guidelines. Loop diuretics (furosemide) have been given historically during the&#xD;
      morcellation portion of HoLEP to promote urine production in the post-operative setting and&#xD;
      to minimize the impact of fluid absorption during long periods of morcellation. The&#xD;
      intra-operative use of 20mg IV furosemide in perioperative HoLEP pathways has been propagated&#xD;
      with the dissemination of HoLEP across North America without evidence to support its routine&#xD;
      administration.&#xD;
&#xD;
      This single-center randomized controlled trial is designed to assess if there is a&#xD;
      significant difference in same day discharge rates after Holmium Laser Enucleation of the&#xD;
      Prostate (HoLEP). We currently attempt to perform HoLEP as a same-day discharge (SDD)&#xD;
      procedure, however one of the main limiting factors in SDD is hematuria. Loop diuretics&#xD;
      (furosemide) have been administered at the time of morcellation as a part of our HoLEP&#xD;
      pathway to increase post-operative urinary output and reduce clinically significant gross&#xD;
      hematuria and clot-formation. The objective of our study will be to assess if SDD rates are&#xD;
      non-inferior in those patients who do not receive furosemide diuretics versus those that do.&#xD;
&#xD;
      Patients will be randomized 1:1 to 20mg of IV lasix versus control. Patients and the&#xD;
      surgeon/post-operative care team (fellow, residents, and nursing team) will be blinded to the&#xD;
      treatment allocation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2023</start_date>
  <completion_date type="Anticipated">August 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized 1:1</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Only the clinical investigator and anesthesiologist/nurse anesthetist will be aware of treatment allocation. The care providers (surgeon, fellow, resident, and nursing team) and patient will be blinded to the treatment allocation. The outcomes assessor will be unblinded at the time of statistical analysis.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Same-day discharge</measure>
    <time_frame>90-days</time_frame>
    <description>Rate of successful same-day discharge after HoLEP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Same-day catheter removals</measure>
    <time_frame>90-days</time_frame>
    <description>Rate of successful same-day catheter removals after HoLEP</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse medical events (hematuria)</measure>
    <time_frame>90-days</time_frame>
    <description>Rate of unplanned Emergency Department (ED) visits/clinic visits related to bleeding/admission/clot evacuation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse medical events (fluid absorption)</measure>
    <time_frame>90-days</time_frame>
    <description>Rate of transurethral resection (TUR) syndrome, vision changes, seizure, hyponatremia, electrolyte abnormality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of post-operative hematuria</measure>
    <time_frame>90-days</time_frame>
    <description>(days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in operative efficiency (enucleation, morcellation, and overall)</measure>
    <time_frame>90-days</time_frame>
    <description>(minutes/gram)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>90-days</time_frame>
    <description>(hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall complications</measure>
    <time_frame>90-days</time_frame>
    <description>Clavien-Dindo Classification</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">138</enrollment>
  <condition>BPH With Urinary Obstruction</condition>
  <condition>BPH</condition>
  <condition>Hematuria</condition>
  <condition>Same Day Discharge</condition>
  <arm_group>
    <arm_group_label>Loop Diuretic (Furosemide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group of patients will receive 20mg of IV furosemide during the morcellation phase of their HoLEP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group of patients will not receive 20mg of IV furosemide during the morcellation phase of their HoLEP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>20mg of IV furosemide injection during the morcellation phase of HoLEP</description>
    <arm_group_label>Loop Diuretic (Furosemide)</arm_group_label>
    <other_name>Lasix</other_name>
    <other_name>Loop diuretic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males 18 -89 undergoing HoLEP&#xD;
&#xD;
          -  Willing to sign the Informed Consent Form&#xD;
&#xD;
          -  Able to read, understand, and complete patient questionnaires.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy or hypersensitivity to furosemide or other loop diuretic&#xD;
&#xD;
          -  Anuric patients or patients with liver failure&#xD;
&#xD;
          -  Patients having a concurrent ureteroscopy +/- laser lithotripsy, percutaneous&#xD;
             nephrolithotomy, or non-urologic surgery at the time of their HoLEP&#xD;
&#xD;
          -  Anticipated need for perineal urethrostomy at the time of HoLEP&#xD;
&#xD;
          -  Patient not undergoing catheter removal and voiding trial at Northwestern Memorial&#xD;
             Hospital&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy E Krambeck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicholas S Dean, MD</last_name>
    <phone>7806906285</phone>
    <email>nicholas.dean@northwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Dean, MD</last_name>
      <email>nicholas.dean@nm.org</email>
    </contact>
    <contact_backup>
      <last_name>Alyssa McDonald</last_name>
      <email>alyssa.mcdonald@northwestern.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Parsons JK, Dahm P, Kohler TS, Lerner LB, Wilt TJ. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA Guideline Amendment 2020. J Urol. 2020 Oct;204(4):799-804. doi: 10.1097/JU.0000000000001298. Epub 2020 Jul 23.</citation>
    <PMID>32698710</PMID>
  </reference>
  <reference>
    <citation>Agarwal DK, Large T, Tong Y, Stoughton CL, Damler EM, Nottingham CU, Rivera ME, Krambeck AE. Same Day Discharge is a Successful Approach for the Majority of Patients Undergoing Holmium Laser Enucleation of the Prostate. Eur Urol Focus. 2022 Jan;8(1):228-234. doi: 10.1016/j.euf.2020.12.018. Epub 2021 Jan 4.</citation>
    <PMID>33414073</PMID>
  </reference>
  <reference>
    <citation>Kuo RL, Paterson RF, Kim SC, Siqueira TM Jr, Elhilali MM, Lingeman JE. Holmium Laser Enucleation of the Prostate (HoLEP): A Technical Update. World J Surg Oncol. 2003 Jun 6;1(1):6. doi: 10.1186/1477-7819-1-6.</citation>
    <PMID>12818001</PMID>
  </reference>
  <reference>
    <citation>Elzayat E, Habib E, Elhilali M. Holmium laser enucleation of the prostate in patients on anticoagulant therapy or with bleeding disorders. J Urol. 2006 Apr;175(4):1428-32. doi: 10.1016/S0022-5347(05)00645-2.</citation>
    <PMID>16516015</PMID>
  </reference>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>November 11, 2022</study_first_submitted>
  <study_first_submitted_qc>November 11, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2022</study_first_posted>
  <last_update_submitted>March 21, 2023</last_update_submitted>
  <last_update_submitted_qc>March 21, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Amy Krambeck</investigator_full_name>
    <investigator_title>Director of The Division of Endourology &amp; Stone Disease</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Furosemide</mesh_term>
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Sodium Potassium Chloride Symporter Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

